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We studied the presence of drug-dependent antibodies (D-DAbs) in
53 patients with AIDS who developed immune hemolytic anemia
(IHA). We examined sera and eluates for the presence of D-DAbs.
Drug antibodies were detected in 43.4 percent (23/53) of the
patients with IHA. Antibodies to more than one drug were detected
in 60.8 percent (14/23) of patients with drug-induced IHA (D-IHA).
The DAT was positive by RBC-bound  IgG in eight patients, RBC-
bound IgG/C3d in nine, IgG/IgA in three, IgG/IgA/C3d in two, and
one patient had RBC-bound C3d only. No drug-independent
antibodies were detected. Our study demonstrates that patients
with AIDS commonly develop D-DAbs. D-IHA should be included
in the differential diagnosis of a falling Hb in AIDS patients
receiving drugs. Immunohematology 2003;19:10–15.
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Drug-induced immune hemolytic anemia (D-IHA) is
a rare but potentially serious event that occurs in about
1 in 1 million of the population.1 The underlying
pathogenesis is not fully understood, but at least three
widely recognized mechanisms, arbitrarily designated
types I, II, and III, appear to be involved in this side
effect of drug treatment.2
The first type (drug adsorption or hapten type) is
usually associated with medications (e.g., the
penicillins, and cephalosporins) that bind covalently to
cell membrane proteins and, acting as haptens, trigger
antibody production specific for the drug (Type I).
Treatment of such patients with the drug at very high
doses sometimes leads to coating of autologous RBCs
with enough drug to allow antibody binding that leads
to hemolysis.3 This type of antibody (IgG-class) can be
detected by showing that it reacts with RBCs coated
with the offending drug in vitro.
In a second type of hemolysis (Type II), patients
develop autoantibodies that do not require drug to be
present to bind to RBCs and cause their destruction
and may perpetuate hemolysis for a period after the
drug is discontinued. This type of antibody is
indistinguishable from those found in warm
autoimmune hemolytic anemia (AIHA). In many cases,
there is little or no clinical effect, but in a few patients
overt hemolysis develops.3,4 It has been postulated that
the drugs (e.g., methyldopa, levodopa, ibuprofen,
mefenamic acid, and naproxen) affect the T suppressor
lymphocyte control of B lymphocytes, permitting the
production of autoantibodies.
Types I and II D-IHA are usually mild, sometimes
even subclinical.5
A third type of D-IHA (Type III) is characterized by
the formation of complement-activating IgG and/or
IgM antibodies that bind to normal RBCs only when
the sensitizing drug or its metabolites (examples
include quinine, rifampin, and tolbutamide) are present
in the fluid phase.
The resulting intravascular hemolysis may be severe
and lead to renal failure or even death. It was thought
that “immune complexes”consisting of antibody bound
to the drug or to a drug-protein complex caused the
reaction. However, the putative immune complexes
have never been convincingly demonstrated, and it is
now generally thought that the provocative drugs
interact noncovalently with certain membrane proteins
to form combinational epitopes or induce conform-
ational changes for which the antibodies are specific.
Alternatively, Type III antibodies may be specific for
secondary conformational changes induced by drug in
the target molecule. This type of drug-dependent anti-
body (D-DAb) can sometimes be identified by an IAT 
in the presence of the sensitizing drug or metabolite.
In contrast to Type I and Type II hemolysis, Type III
hemolysis is often severe, characterized by acute
intravascular hemolysis. In 30–50 percent of the
patients, renal failure also occurs, and numerous fatal
outcomes have been described.6
In most cases, only one of the three mechanisms is
operative;however, combinations of Types I and III and
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Types II and III have been described.The involvement
of different mechanisms in causing hemolysis in a
single patient has been reported and may be relatively
common.6–8 It has been suggested that in patients with
D-IHA, such complicated responses are the rule rather
than the exception.9
Anemia is the most common hematologic
abnormality seen in patients with AIDS.10–12 The etiology
of anemia in HIV infections is often multifactorial.
Several studies have documented a high incidence of
positive DATs in AIDS patients,13,14 but immune
hemolytic anemia (IHA) is a rare complication.15
Reports of D-IHA in AIDS patients are rare, and to
our knowledge,only one has been related to perinatally
acquired AIDS16,17 or to antiretroviral drugs.18
We recently encountered some patients with AIDS
with IHA who had D-DAbs present.19
Materials and Methods
Patients
IHA was diagnosed in patients with AIDS by a
positive DAT, falling Hb, reticulocytosis, increased LDH,
and indirect bilirubin. Other causes of hemolysis,
including hereditary microangiopathic hemolytic
anemia, were excluded. If appropriate, follow-up
studies were performed to confirm the clinical
suspicion of D-IHA. At the time of this study, no
patients were receiving highly active antiretroviral
therapy.
Samples
Between January 1, 1997, and June 30, 1999, blood
samples from patients with AIDS and IHA were
forwarded to our laboratory for investigation of a
possible D-IHA. Studies were carried out on venous
blood that had been collected using K2EDTA as an
anticoagulant. All samples were tested within 48 hours
of collection.
To eliminate any residual drug and its metabolites,
the patient’s serum was dialyzed in vitro against NaCl.
Antiglobulin test 
Standardized serologic procedures, including the
IAT and DAT (polyspecific and monospecific anti-IgG,
-IgM, and -C3d) were performed using the Gel Test
(DiaMed, Cressier sur Morat, Switzerland) according to
the manufacturer’s instructions.
Drug-dependent antibody determinations 
The drugs tested were isoniazid (Nicotibina,
Aventis), sulfisoxazole (Bactrim, Roche), rifampicin
(Rifadin, Aventis), pyrazinamide (Pirazinamide Veintar,
Larjan), fluconazole (Mutun, Raffo), streptomycin
(Bronquibiotic, Sanofi-Syntelabo), ofloxacin (Floxil,
Janssen-Cilag), acyclovir (Lisovyn, Elea), cephalothin
(Keflin, Lilly), ceftazidine (Fortum, Glaxo-Wellcome),
ceftriaxone (Acantex, Roche), ciprofloxacin (Ciriax,
Roemmers), etambutol (Etambutol Martian, Kampel
Martian), rifabutin (Mycobutin, Pharm & Upjohn),
fenitoine (Epamin, Parke Davis), paracetamol
(Paracetamol Lazar, Lazar), pirimetamine (Daraprim,
Glaxo-Wellcome), and vancomycin (Vancocin, Lilly).
All testing of D-DAbs was performed using the
Micro-Typing System (DiaMed, Cressier sur Morat,
Switzerland) as previously described,20 with slight
modifications.21–23
Drug-coated RBCs
Separate aliquots of RBCs were coated by the
method of Garratty24 with some modifications21–23;
briefly: if available, only IV preparations of drugs to be
tested were used. If only tablet form was available,
tablets were crushed before mixing in deionized water,
and the sediment was discarded after centrifugation.
All drugs were diluted to a concentration of 40 mg/mL,
in barbital-buffered saline (BBS). For cefotetan and
cephalothin, 1 mL of group O, washed, packed reagent
RBCs was incubated in 10 mL of a drug-BBS solution for
1 hour at room temperature. The treated RBCs were
multiply washed in normal saline (NS) and tested by
gel  with the patient’s serum or eluate.
When testing cefotetan- or cephalothin-coated
RBCs, the serum was diluted 1 in 20 with NS. Controls
were prepared by incubation of the RBCs in identical
proportions and at identical temperatures in BBS with
no drugs added, and tested in parallel.
IAT in presence of drug (IAT-D)
Before testing with patients’ sera, the different
drugs were diluted to 1 mg/mL in PBS, and the final pH
adjusted to pH 7.4, followed by the IAT including the
drug-solution as previously described.20–23 Controls
were set up in parallel without drugs.
Eluate preparation
Acid eluates were prepared from those D-
DAb–coated RBCs whose corresponding serum
samples reacted only with drug-coated RBCs. The
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eluates were prepared using a commercial
kit (Elu-Kit II, Gamma Biologicals, Inc.,
Houston, TX). After 1998, all acid eluates
were prepared after washing the patients’
RBCs with PBS or LISS. Because of “falsely
positive last washes,” many eluates were
prepared after an increased number (6 to
12) of washes of the RBCs with PBS or 4°C
LISS.25
Results 
Between January 1, 1997, and June 30,
1999, IHA was detected in 64 patients with
AIDS. Because of the lack of critical
information, 11 patients were excluded
from the analysis. Of the remaining 53
patients, IHA was attributed to drug
therapy in 23 (43.4%) patients in whom
hemolysis had ceased upon withdrawl of
drug therapy.
The median age of the 27 men and 
26 women included in the current
investigation was 54 years (range, 23–73
years).
The DAT was positive by anti-IgG in
eight patients, by anti-IgG/C3d in another
nine, by anti-IgG/IgA in three, by anti-
IgG/IgA/C3d in two,and by anti-C3d in only
one (Table 1). The strength of reactions
with polyspecific anti-human globulin
reagents ranged from weak + to 2+.
The total of D-DAbs detected was 50
(in 23 patients),of which 24 were detected
by IAT-D, 18 by drug-coated RBCs, and
eight by both IAT-D and drug-coated RBCs
(Table 2).
Drug-independent antibodies were not
detected.
Fourteen of our 23 patients with D-IHA
(60.8%) had antibodies to more than one
drug. In six patients the immune response
was to two drugs. Five patients formed D-
DAbs against three drugs. Another two
patients formed D-DAbs against four drugs,
and one against six drugs. The drugs most
frequently implicated were isoniazid
(9/50), sulfisoxazole (8/50), rifampicin
(8/50), pyrazinamide (6/50), fluconazole
(3/50), streptomycin (3/50), ofloxacin
(2/50), and one each of ceftazidine,
Table 1. Serology and treatment of the 23 patients with D-DAbs*
D-DAb detected with
Patient DAT anti- Drug Coated RBCs IAT-D† Treatment
Serum Eluate
1. IgG/IgA pyrazinamide 2+ 3+ NR‡ IVIG
fluconazole 2+ 3+ NR 2 RBC Tx§
isoniazid 2+ 2+ NR
2. IgG/IgA sulfisoxazole NR NT|| 4+
ofloxacin NR NT 4+
rifabutin NR NT 3+
3. IgG/IgA/C3db sulfisoxazole NR NT 2+ IVIG 1 RBC Tx
4. IgG/IgA sulfisoxazole NR NT 3+
5. IgG/C3d ofloxacin 3+ 4+ NR
fluconazole 2+ 2+ NR
fenitoine 2+ 3+ NR
pirimetamine 3+ 3+ NR
6. IgG fluconazole NR NT 4+
7. IgG/IgA/C3d pyrazinamide 3+ 3+ NR IVIG 1 RBC Tx
isoniazid 1+ 2+ NR
8. IgG/C3d sulfisoxazole 2+ 3+ NR
rifampicin 2+ 3+ NR
pyrazinamide 3+ 2+ NR
9. IgG vancomycin NR NT 4+
10. IgG isoniazide NR NT 3+
rifampicin NR NT 2+
pyrazinamide NR NT 3+
paracetamol NR NT 3+
11. IgG ceftrizone 3+ 4+ 4+
pyrazinamide 3+ 4+ 3+
etambutol 2+ 4+ 3+
acyclovir 2+ 2+ NR
isoniazid 2+ 3+ NR
rifampicin 2+ 3+ NR
12. IgG/C3d isoniazid NR NT 2+
rifampicin 2+ 3+ 2+
13. IgG/C3d streptomycin 2+ 3+ NR
14. IgG sulfisoxazole NR NT 2+
ciprofloxacin NR NT 2+
streptomycin 2+ 3+ NR
15. IgG + C3d sulfisoxazole NR NT 3+ Corticosteroids
rifampicin NR NT 3+
16. IgG + C3d pyrazinamide NR NT 2+
isoniazid NR NT 3+
17. IgG sulfisoxazole NR NT 3+
isoniazid NR NT 2+
18. C3d isoniazid NR NT 3+ 4 RBC Tx
19. IgG + C3d rifampicin 2+ 3+ 4+ Corticosteroids
IVIG 1 RBC Tx
20. IgG ceftazidine NR NT 3+ 6 RBC Tx
rifampicin 2+ 2+ NR
21. IgG + C3d cephalothin 3+ 3+ 3+ IVIG
22. IgG streptomycin 2+ 3+ 3+
sulfisoxazole NR NT 3+
isoniazid 2+ 2+ NR
23. IgG + C3d rifampicin NR NT 3+ IVIG
*Drug-dependent antibodies
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paracetamol, ciprofloxacin, fenitoine, pirimetamine,
ceftriaxone, etambutol, acyclovir, rifabutin,
vancomycin, and cephalothin (Table 2).
Serum samples from 12 patients whose D-DAbs
were only detected versus drug-coated RBCs yielded
positive eluates versus the corresponding drug(s)
(Table 1). All eluates were nonreactive versus
untreated RBCs.
Because many drugs cause mechanical hemolysis
or spontaneous aggregation of RBCs, all positive
findings with a patient’s serum  and eluate were
considered valid only when normal sera were shown to
be nonreactive in the same test system.
Despite discontinuation of the drug, nine of the 23
patients with D-DAbs (39%) needed additional
therapeutic support. When necessary and available,
IVIG, Sandoglobulin®,26 RBC transfusions, and
corticosteriods were used (Table 1).
Despite multiple attempts to contact the patients,
long term follow-up was not available.
Discussion
Patients with AIDS may develop several hematologic
complications, including anemia, leukopenia, and
thrombocytopenia.11,12 Several case series13,14 have
shown that IHA may occur. To our knowledge, the
natural history of HIV-associated IHA is not well
described.
The clinical presentation of HIV-associated IHA
may vary from a mild form, to a moderate anemia with
splenomegaly, to fulminant hemolysis with marked
spherocytosis. The serologic findings in AIDS are
variable, including coating of RBCs by both IgG and C3
or IgG alone. In addition, the simultaneous presence of
both cold and warm autoantibodies has been reported
to be more common in HIV-associated IHA than in non-
HIV.27 However, the mechanism by which HIV-infected
patients develop (auto) IHA and the clinical
importance and  clinical/serologic associations of IHA
in AIDS are controversial.
Our study demonstrates that patients with AIDS
may develop D-DAbs with IHA. The laboratory findings
gave evidence that the hemolysis was due to D-DAbs.
It could not be determined by our serologic methods
whether the reactions of these antibodies with RBCs
were dependent on the presence of the native drug
and a metabolite or on the native drug alone.
The presence of D-IHA induced by more than one
drug permits us to suggest the following hypotheses:
• Presence of identical epitopes in different drugs:
Despite our effort, we could not demonstrate (by
inhibition of D-DAbs) whether the serologic
result was caused by the immune response
against a similar epitope in different drugs or
(more probably) by a different population of D-
DAbs against several drugs. We did not see any
cases of D-IHA in which the drug was capable of
inhibiting the causative antibody, even D-DAb-
Type I.
• Predisposition of patients with AIDS to develop
D-IHA: HIV infection is associated with an
increased incidence of autoantibodies.28 From
the beginning of the disease, idiopathic IHA in
AIDS has been associated with (1) immune-
complex-associated IgG that adheres to RBCs via
C3b receptors rather than via autoantibodies
directed against RBCs13,29,30 or (2) association 
with infectious agents (Mycoplasma avium
intracellulare, Cytomegalovirus, Pneumocystis
carinii, Mycobacterium tuberculosis,
Histoplasma capsulatum, or related malignant
lymphoma)15,31–34. In this context, both
mechanisms may be nonspecific consequences
of derangement of the immune system’s
homeostasis, leading to exacerbated function and
expression of preexisting autoreactive elements.
Immune hemolytic anemia in AIDS patients




Drug RBCs IAT-D* methods Total
isoniazid 4 5 9
sulfisoxazole 1 7 8
rifampicin 2 3 3 8
pyrazinamide 3 2 1 6
fluconazole 2 1 3
streptomicyn 2 1 3












Total 18 24 8 50
*IAT with drug added
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When this immune system is challenged by
polymedication,which happens frequently in our
institution, patients may develop D-DAbs.
In this study, D-IHA was observed in 23 (43.4%) of
patients with AIDS evaluated during the study period.
Despite this, the cited frequency should be approached
with some caution since idiopathic IHA is more
common, and a history of drug therapy may be a
coincidental finding and does not necessarily mean
that the drug is to blame. We only included in this
study patients with a serologic confirmation of the
presence of D-DAb and a history of hemolysis that
ceased after the drug was stopped. Patients with
continuing IHA,history of  previous drug ingestion,and
drug-independent RBC autoantibodies were excluded
from the current study.
Elevated IgG levels have been associated with
positive DATs in patients with nonreceptor-mediated
adsorption of IgG onto RBC membranes.13,29 IgG levels
were elevated in AIDS patients when compared with
those of a control group, but the IgG levels in the
population we studied did not differ from those of
controls (data not shown).
IHA is a highly uncommon adverse reaction to drugs,
although the incidence might well be underestimated.
That the majority of the few well-documented cases of D-
IHA in AIDS were diagnosed at our institution certainly
reflects a different level of suspicion rather than a truly
higher incidence.35 Thus, it is tempting to speculate that
the incidence of D-IHA is far higher than previously
estimated, i.e., one case per million.1
In contrast, we had some problems in investigating
D-DAbs, i.e., interpreting the negative serologic results
associated with IHA accurately, for the following
reasons: (1) It is difficult to interpret negative reactions
if the drug has not been described previously in the
literature (because it is unlikely there is a positive
control). (2) Prozones have been reported,36 so we had
to try different drug concentrations before assuming a
negative serologic result was correct. Both points
remain unresolved.
We believe that physicians treating HIV patients
should be aware that drug treatment can lead to RBC
sensitization associated with sudden and unpredictable
hemolysis,which may be fatal, and thus, therapy should
include discontinuation of drug therapy.
Although many questions concerning the
pathophysiology, clinical significance, and treatment of
D-IHA in AIDS remain unanswered, as the incidence of
this worldwide infectious disease continues to increase,
we feel it is important to recognize that D-IHA should
be considered and included in the differential diagnosis
of a falling Hb in an AIDS patient receiving drugs.
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